A Novo Nordisk Sponsored Promotional Satellite Symposium. This Promotional satellite symposium has been organised and funded by Novo Nordisk Health Care AG, Switzerland. This promotional satellite symposium is intended for healthcare professionals only and will include clinical trial data about Novo Nordisk medicines. Veeva Job: UK24SOM00035 ; Date of preparation: October 2024

This promotional Satellite Symposium is organised and funded by Rhythm Pharmaceuticals Netherlands B.V. and is intended for healthcare professionals only. Access the Prescribing Information and adverse event reporting details here: https://path4hcps.com/UK-Pl.pdf Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Rhythm Pharmaceuticals on [email protected]. Veeva Job: UK-IC1-2400022, Date of Preparation: October 2024

A promotional satellite symposium organised by Chiesi Global Rare Diseases at the 62nd Annual ESPE Meeting, Liverpool, UK This promotional satellite symposium is organised and funded by Chiesi Global Rare Diseases and is only open to healthcare professionals. Chiesi medicines will be discussed at this symposium. Adverse event reporting information and prescribing information will be available at the symposium. UK-MYA-2400027 | Date of preparation September 2024

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Healthcare professionals should report adverse events in accordance with their local requirements. Adverse events should also be reported to BioMarin on + 1 415 506 6179 or [email protected] VOXZOGO® (vosoritide) is not licensed in the UK but is licensed in the European Union (EU). Information in this symposium is based upon the EU VOXZOGO® label. Please refer to your local prescribing Information before prescribing VOXZOGO® . VOXZOGO® is indicated in the EU for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. VOXZOGO® Abbreviated Prescribing Information: https://bit.ly/VOXZOGO_aPI_June2024 This symposium is for Healthcare Professionals only and is organised and sponsored by BioMarin EUCAN-VOX-00541 – August 2024

This promotional symposium has been organised and funded by Pfizer and is intended for healthcare professionals only. Pfizer products will be discussed. Pfizer Satellite Symposium at the European Society for Paediatric Endocrinology (ESPE) Congress 2024 PP-NGE-GBR-0950 © 2024 Pfizer Inc. All rights reserved. October 2024

This promotional meeting is organised and funded by Novo Nordisk and is intended for healthcare professionals only. Veeva PromoMats Doc. details: UK24SEMO00147, September 2024

A satellite symposium provided by PeerVoice. This activity is supported by an educational grant from Sanofi. Learning Objectives: - Explain the rationale for conducting autoantibody screening for pre-symptomatic T1D - Identify current recommendations and practical considerations for conducting autoantibody screening for T1D - Use the results of autoantibody screening for T1D to inform education, monitoring, follow-up, and management plans for individual patients - Evaluate the mechanisms of, available efficacy and safety data for, and practical considerations related to novel therapies targeting the underlying pathogenesis of T1D